This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2005;293:413-414.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—Now that rofecoxib has been pulled from the market due to life-threatening adverse cardiovascular events, which had reportedly been evident 4 years ago, patients and physicians are left with many questions regarding the safety of other drugs that preferentially inhibit the cyclooxygenase-2 (COX-2) enzyme and the shortcomings in the government’s drug monitoring system in general.

The recent controversy over rofecoxib and other COX-2 inhibitors has raised questions regarding the current drug approval and monitoring systems in the United States. (Photo credit: AP/Wide World Photos)

Researchers and clinicians met here at the annual conference of the Osteoarthritis Research Society International in December to discuss the issues and to look at what should be done to safeguard patients.

Daniel Solomon, MD, MPH, of Brigham and Women’s Hospital, in Boston, said he hopes the incident leads to the development of an improved drug safety system. "I think when safety . . . [Full Text of this Article]

NEED FOR POSTMARKETING STUDIES



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?